KOBAYASHI Hirohito
Department School of Medicine(Tokyo Women's Medical University Adachi Medical Center), School of Medicine Position Associate Professor |
|
Article types | Review article |
Language | English |
Peer review | Peer reviewed |
Presence of invitation | Invited paper |
Title | γδ T Cell Immunotherapy-A Review. |
Journal | Formal name:Pharmaceuticals (Basel, Switzerland) Abbreviation:Pharmaceuticals (Basel) ISSN code:14248247/14248247 |
Domestic / Foregin | Foregin |
Volume, Issue, Page | 8(1),pp.40-61 |
Author and coauthor | Kobayashi Hirohito, Tanaka Yoshimasa |
Publication date | 2015/02 |
Summary | Cancer immunotherapy utilizing Vγ9Vδ2 T cells has been developed over the past decade. A large number of clinical trials have been conducted on various types of solid tumors as well as hematological malignancies. Vγ9Vδ2 T cell-based immunotherapy can be classified into two categories based on the methods of activation and expansion of these cells. Although the in vivo expansion of Vγ9Vδ2 T cells by phosphoantigens or nitrogen-containing bisphosphonates (N-bis) has been translated to early-phase clinical trials, in which the safety of the treatment was confirmed, problems such as activation-induced Vγ9Vδ2 T cell anergy and a decrease in the number of peripheral blood Vγ9Vδ2 T cells after infusion of these stimulants have not yet been solved. In addition, it is difficult to ex vivo expand Vγ9Vδ2 T cells from advanced cancer patients with decreased initial numbers of peripheral blood Vγ9Vδ2 T cells. In this article, we review the clinical studies and reports targeting Vγ9Vδ2 T cells and discuss the development and improvement of Vγ9Vδ2 T cell-based cancer immunotherapy. |
DOI | 10.3390/ph8010040 |
PMID | 25686210 |